Iovance Biotherapeutics Current Valuation vs. Number Of Employees
| IOVA Stock | USD 9.12 0.15 1.62% |
For Iovance Biotherapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Iovance Biotherapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Iovance Biotherapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Iovance Biotherapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Iovance Biotherapeutics over time as well as its relative position and ranking within its peers.
Iovance |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iovance Biotherapeutics. If investors know Iovance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iovance Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Revenue Per Share 0.327 | Quarterly Revenue Growth 123.851 | Return On Assets (0.29) | Return On Equity (0.57) |
The market value of Iovance Biotherapeutics is measured differently than its book value, which is the value of Iovance that is recorded on the company's balance sheet. Investors also form their own opinion of Iovance Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iovance Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iovance Biotherapeutics' market value can be influenced by many factors that don't directly affect Iovance Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iovance Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iovance Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iovance Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Iovance Biotherapeutics Number Of Employees vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Iovance Biotherapeutics's current stock value. Our valuation model uses many indicators to compare Iovance Biotherapeutics value to that of its competitors to determine the firm's financial worth. Iovance Biotherapeutics is considered the number one company in current valuation category among its peers. It also is currently regarded as number one stock in number of employees category among its peers . The ratio of Current Valuation to Number Of Employees for Iovance Biotherapeutics is about 4,500,490 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Iovance Biotherapeutics' earnings, one of the primary drivers of an investment's value.Iovance Biotherapeutics' Earnings Breakdown by Geography
Iovance Current Valuation vs. Competition
Iovance Biotherapeutics is considered the number one company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 3.04 Billion. Iovance Biotherapeutics totals roughly 2.51 Billion in current valuation claiming about 83% of equities under Health Care industry.
Iovance Number Of Employees vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Iovance Biotherapeutics |
| = | 2.51 B |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
Iovance Biotherapeutics |
| = | 557 |
Employee typically refers to an individual working under a contract of employment, whether oral or written, express or implied, and has recognized his or her rights and duties. Most officers of corporations are included as employees and contractors are generally excluded.
Iovance Number Of Employees vs Competition
Iovance Biotherapeutics is currently regarded as number one stock in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,011. Iovance Biotherapeutics totals roughly 557 in number of employees claiming about 55% of equities under Health Care industry.
Iovance Biotherapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Iovance Biotherapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Iovance Biotherapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Iovance Biotherapeutics' change in net profit over the period of time. It can combine multiple indicators of Iovance Biotherapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 2.5 M | 2.7 M | |
| Operating Income | -460.6 M | -437.5 M | |
| Income Before Tax | -447.5 M | -425.1 M | |
| Net Loss | -444 M | -421.8 M | |
| Total Other Income Expense Net | 13 M | 13.7 M | |
| Income Tax Expense | -3.5 M | -3.3 M | |
| Net Loss | -433 M | -411.3 M | |
| Non Operating Income Net Other | 518.6 K | 492.7 K | |
| Net Loss | -356.3 M | -338.5 M | |
| Interest Income | 11.6 M | 12.2 M | |
| Net Interest Income | 11.6 M | 12.2 M | |
| Change To Netincome | 97.6 M | 102.5 M | |
| Net Loss | (1.89) | (1.98) | |
| Income Quality | 0.81 | 0.54 | |
| Net Income Per E B T | 0.99 | 0.78 |
Iovance Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Iovance Biotherapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Iovance Biotherapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Iovance Biotherapeutics' important profitability drivers and their relationship over time.
Use Iovance Biotherapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Iovance Biotherapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Iovance Biotherapeutics will appreciate offsetting losses from the drop in the long position's value.Iovance Biotherapeutics Pair Trading
Iovance Biotherapeutics Pair Trading Analysis
The ability to find closely correlated positions to Iovance Biotherapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Iovance Biotherapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Iovance Biotherapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Iovance Biotherapeutics to buy it.
The correlation of Iovance Biotherapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Iovance Biotherapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Iovance Biotherapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Iovance Biotherapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Iovance Biotherapeutics position
In addition to having Iovance Biotherapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Real Estate ETFs Thematic Idea Now
Real Estate ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Real Estate ETFs theme has 66 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Real Estate ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis. For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
To fully project Iovance Biotherapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Iovance Biotherapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Iovance Biotherapeutics' income statement, its balance sheet, and the statement of cash flows.